drugset
drugset / Trial / NCT05022004

A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT05022004 ↗

Phase 3 Completed 599 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a randomized, Investigator-masked, multi-center, parallel group, therapeutic equivalence study with clinical endpoint.

Timeline

Start
2021-12-20
Primary completion
2022-12-29
Completion
2023-01-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Brinzolamide Small molecule — Other

Indications

ocular hypertension open-angle glaucoma